Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

As we start the new year, many of us are focusing on diet, exercise, healthy living and our general wellbeing. But did you ...

Research analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research report issued to clients and investors on Tuesday. The brokerage set ...

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20 ...

ONS-5010 is an investigational ophthalmic formulation of bevacizumab, a vascular endothelial growth factor inhibitor, under development as an intravitreal injection.

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...

Cognition Therapeutics, Inc. (NASDAQ:CGTX – Get Free Report) has been given an average rating of “Moderate Buy” by the six ...

Investors with a high tolerance for risk might want to take a look at the speculative ASX stock in this … The post Why this ...

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

Goji berries have been linked to cholesterol reduction and improved heart health, as highlighted by an expert in a BBC Good ...